Myriad reiterated at market outperform by JMP

Myriad Genetics, Inc. was reiterated at market outperform and a $25 price target by JMP Securities analyst Charles C. Duncan on news that the company reported positive second-quarter 2006 financial results. Total revenues came in at $27.3 million, higher than Jefferies' estimate of $26.9 million and consensus estimate $26.7 million. Shares of the Salt Lake City biopharmaceutical company were up $1.42, or 6.74%, at $22.50 on volume of 991,954 shares versus the three-month running average of 335,877 shares. (Nasdaq: MYGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.